ACC 2018 Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.
ACC 2018 In post-MI patients with a low LVEF, WCD reduced total mortality in the immediate post-MI period (<90 days), but not sudden cardiac death.
ACC 2018 In the digital mSToPS trial using patient-generated data, a wearable ECG patch improved the rate of AF diagnosis at 1 year compared to routine care.
ACC 2018 When clinical characteristics were combined with genetic information to inform the choice of P2Y12 inhibitor after ACS, patients experienced 42% fewer MI, stroke, CV death or major bleeding.
ACC 2018 Treatment with dabigatran significantly reduced the risk of thrombotic complications in patients with MINS, as identified by hsTnT level, in the MANAGE study.
ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.
ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.
ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.
In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.
Phase 3 study data with bempedoic acid show 28% additional LDL-c lowering on background therapy and 33% reduction of hsCRP in patients with atherosclerotic CVD or at high risk for ASCVD.
A preclinical study shows that DS-9001a interferes with PCSK9 binding to the LDL receptor and PCSK9-mediated LDLR degradation, and lowers LDL-c, and it is produced in a microbial production system.
12-Week treatment with GPR119 agonist DS-8500a lowers HbA1c, FPG and 2hPPG as compared with placebo, albeit to a lesser extend than sitagliptin, but it also lowered total cholesterol, LDL-c and TG.